Welcome to our dedicated page for Dianthus Therapeutics /DE/ SEC filings (Ticker: DNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Dianthus Therapeutics /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Dianthus Therapeutics /DE/'s regulatory disclosures and financial reporting.
Dianthus Therapeutics CEO and President Garcia Marino reported multiple insider trades dated August 7, 2026. He exercised stock options to acquire 166,000 shares of common stock at an exercise price of $8.44 per share, then on the same date sold 166,000 common shares in a series of open‑market or private transactions at weighted average prices such as $107.49, $108.05 and $110.76 per share. Footnotes state that the reported transaction was effected under a Rule 10b5‑1 trading plan adopted on May 8, 2026, and that the options, expiring June 6, 2032, began vesting on November 1, 2022 with the remainder vesting in equal monthly installments over three years, subject to continued service.
DNTH reporting person Adam M. Veness filed to sell 3,833 shares of common stock, expected on August 7, 2026, following an exercise of stock options for cash. The filing also lists prior Rule 10b5-1 plan sales of 30,000 common shares on June 17, 2026 for $2,424,033.00.
Dnth Holdings Inc. received a notice of proposed sale of common stock under Rule 144. A broker, Morgan Stanley Smith Barney LLC Executive Financial Services, is listed to handle the potential sale of 126,000 shares of common stock on NASDAQ on or after August 7, 2026. The shares relate to an exercise of options under a registered plan. Common shares outstanding are reported as 55,934,378 as context for the size of this proposed transaction.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 6,632,303 shares of Dianthus Therapeutics Inc. common stock, representing 12.1% of the class. The firm holds sole voting power over 6,454,315 shares and sole dispositive power over 6,632,303 shares, with no shared voting or dispositive power. T. Rowe Price Investment Management, Inc. states that this report should not be construed as an admission that it is the beneficial owner of these securities and expressly denies such beneficial ownership.
DIANTHUS THERAPEUTICS INC reported that T. Rowe Price Investment Management, Inc. holds a significant position in its common stock. T. Rowe Price Investment Management is shown as beneficially owning 3,888,456 shares of common stock, representing 7.1% of the outstanding class.
The firm reports sole voting power over 3,884,903 shares and sole dispositive power over 3,888,456 shares, with no shared voting or dispositive power. T. Rowe Price Investment Management states that this filing should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.
Dianthus Therapeutics, a clinical-stage biotech focused on severe autoimmune diseases, reported a net loss of $50.2M for the quarter and $91.0M for the six months ended June 30, 2026, driven mainly by rising R&D spending on its claseprubart program and discovery work.
R&D expenses reached $48.7M in the quarter and $83.2M year-to-date, while G&A totaled $13.6M and $26.0M, respectively. License revenue from its Tenacia partnership contributed $0.8M in the quarter. A March 2026 equity offering raised $719.0M, alongside ATM share sales of $58.7M, lifting liquidity, with cash and cash equivalents of $110.5M and marketable securities of $1.08B within total assets of $1.21B at June 30, 2026. Management states that existing cash, cash equivalents and investments are expected to fund obligations for at least twelve months beyond the financial statement issuance date, even as the company continues to invest heavily in claseprubart, new candidate DNTH212 and broader pipeline activities.
Dianthus Therapeutics, Inc. reported second-quarter 2026 results and highlighted progress across its autoimmune pipeline. Lead asset claseprubart, a subcutaneous aC1s inhibitor, advanced with initiation of the Phase 3 EMERGE registrational trial in generalized myasthenia gravis, with top-line results anticipated in 2H 2028. In chronic inflammatory demyelinating polyneuropathy, the Phase 3 CAPTIVATE trial showed a 75% response rate in an interim analysis of the first 40 Part A participants, exceeding the 50% target, and the Phase 2 MoMeNtum trial in multifocal motor neuropathy completed enrollment above its 36-patient target, with 46 patients and top-line data expected in December 2026.
The company is building a rheumatology franchise with DNTH212, with Phase 1 healthy volunteer data anticipated by year-end 2026, and advancing DNTH312, a next-generation bifunctional fusion protein aiming to be Phase 1 ready by year-end 2027. Cash, cash equivalents and investments totaled approximately $1.2 billion as of June 30, 2026, providing expected runway into 2030. For the quarter, research and development expenses were $48.7 million and general and administrative expenses were $13.6 million. Net loss was $50.2 million, or $0.90 per share, compared with $31.6 million, or $0.88 per share, in the prior-year quarter.